InsidersTradesSigma
Edesa Biotech, Inc.: insider trades · United States · SEC (Form 4)
SEC:edesa-biotech-inc-fa3abdUS·SEC (Form 4)Mcap 18M€Healthcare
Discover the full insider trade history of Edesa Biotech, Inc., a listed equity based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Healthcare sector, Edesa Biotech, Inc. has published 16 public disclosures. Market capitalisation: €17.6m. The latest transaction was disclosed on 30 June 2022 — Acquisition. Among the most active insiders: Nijhawan Pardeep. All data is openly available.
16
Insider Decl.
0
Thresholds
€75,770
16 ops.
Buy Volume
·
0 ops.
Sell Volume
Financial data
FY ended September 2025 · cache
9.00 €
Analyst consensus
2 analystsStrong buy
9.00 €Target 14.00 €(+56%)19.00 €
Income statement
Net income−7.2 M€0.0% margin
Valuation
P/Book20.1x
Beta1.28
Balance sheet & cash
Market cap17.6 M€
Free Cash Flow−7.3 M€
Profitability & ownership
ROE-96.4%
ROA-55.3%
% insiders15.0%
% institutions43.7%
Last declaration on 30 June 2022
Declarations16 total
Executives▲Purchase38SEC
€4,2913,000 shares@ €1.43040.024% mcap17.9% of flow
Common Shares
SEC:0001654954-22-009005:0·
Ideal exit: 26 Mar 2023 (T+270)
Executives▲Purchase◆Signal · 50SEC
€4,5673,000 shares@ €1.52230.026% mcap19.0% of flow
Common Shares
SEC:0001654954-22-008536:0·
Ideal exit: 13 Mar 2023 (T+270)
Executives▲Purchase◆Signal · 52SEC
€8,9435,000 shares@ €1.78870.051% mcap17.3% of flow
Common Shares
SEC:0001654954-22-007684:0·
Ideal exit: 21 Feb 2023 (T+270)
Executives▲Purchase◆Signal · 51SEC
€5,6993,500 shares@ €1.62820.032% mcap23.8% of flow
Common Shares
SEC:0001654954-22-007559:0·
Ideal exit: 19 Feb 2023 (T+270)
Executives▲Purchase◆Signal · 49SEC
€3,3532,000 shares@ €1.67630.019% mcap6.5% of flow
Common Shares
SEC:0001654954-22-007509:0·
Ideal exit: 18 Feb 2023 (T+270)
Executives▲Purchase◆Signal · 50SEC
€5,3932,000 shares@ €2.69660.031% mcap10.4% of flow
Common Shares
SEC:0001654954-22-004413:0·
Ideal exit: 26 Dec 2022 (T+270)
Executives▲Purchase◆Signal · 50SEC
€5,4632,000 shares@ €2.73170.031% mcap10.6% of flow
Common Shares
SEC:0001654954-22-004245:0·
Ideal exit: 25 Dec 2022 (T+270)
Executives▲Purchase◆Signal · 50SEC
€5,4402,000 shares@ €2.71990.031% mcap10.5% of flow
Common Shares
SEC:0001654954-22-004118:0·
Ideal exit: 24 Dec 2022 (T+270)
Executives▲Purchase◆Signal · 50SEC
€6,9372,000 shares@ €3.46830.039% mcap13.4% of flow
Common Shares
SEC:0001654954-22-003483:0·
Ideal exit: 13 Dec 2022 (T+270)
Executives▲Purchase◆Signal · 45SEC
€1,171397 shares@ €2.94850.0066% mcap2.3% of flow
Common Shares
SEC:0001654954-22-003409:0·
Ideal exit: 12 Dec 2022 (T+270)
Executives▲Purchase◆Signal · 48SEC
€5,1162,000 shares@ €2.55780.029% mcap9.9% of flow
Common Shares
SEC:0001654954-22-003224:0·
Ideal exit: 10 Dec 2022 (T+270)
Executives▲Purchase◆Signal · 47SEC
€3,1891,250 shares@ €2.55150.018% mcap13.3% of flow
Common Shares
SEC:0001654954-22-003144:0·
Ideal exit: 9 Dec 2022 (T+270)
Executives▲Purchase◆Signal · 48SEC
€5,7722,000 shares@ €2.88620.033% mcap11.1% of flow
Common Shares
SEC:0001654954-22-003095:0·
Ideal exit: 6 Dec 2022 (T+270)
Executives▲Purchase◆Signal · 46SEC
€2,9101,000 shares@ €2.91040.016% mcap12.1% of flow
Common Shares
SEC:0001654954-22-002936:0·
Ideal exit: 5 Dec 2022 (T+270)
Executives▲Purchase◆Signal · 45SEC
€4,1931,500 shares@ €2.79530.024% mcap8.1% of flow
Common Shares
SEC:0001654954-22-002850:0·
Ideal exit: 4 Dec 2022 (T+270)
Executives▲Purchase◆Signal · 45SEC
€3,3331,250 shares@ €2.66670.019% mcap13.9% of flow
Common Shares
SEC:0001654954-22-002765:0·
Ideal exit: 3 Dec 2022 (T+270)
16 of 16 declarations